Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SNDX
SNDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SNDX News
Syndax Pharmaceuticals Grants Stock Options to New Employees
6d ago
Yahoo Finance
Syndax (SNDX) Q4 2025 Earnings Call Transcript
Feb 27 2026
NASDAQ.COM
Syndax Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 27 2026
seekingalpha
Syndax Pharma Reports Q4 Loss and Revenue Surge
Feb 27 2026
NASDAQ.COM
Syndax Pharmaceuticals Reports Q4 Earnings and 2026 Outlook
Feb 26 2026
seekingalpha
Syndax Pharmaceuticals Q4 Earnings Preview
Feb 25 2026
seekingalpha
Syndax Partners with WODA to Expand Access to Revuforj in Multiple Regions
Jan 07 2026
Globenewswire
Syndax Pharmaceuticals Inc. Offers 10.4% Annualized Return on $13 Put Options
Dec 29 2025
NASDAQ.COM
Syndax's Revuforj® Wins Best New Drug at 2025 Scrip Awards
Dec 12 2025
Globenewswire
Syndax's Revuforj® Wins Best New Drug at 2025 Scrip Awards
Dec 12 2025
Newsfilter
JPMorgan Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $33, Keeps "Overweight" Rating Intact
Nov 17 2025
Yahoo Finance
UBS Reiterates Buy Rating for Syndax Pharmaceuticals and Increases Price Target to $38
Nov 04 2025
Benzinga
Syndax aims for $10B market following Revuforj's NPM1 approval and a 21% increase in Q3 revenue.
Nov 03 2025
SeekingAlpha
Syndax to Hold In-Person and Webcast ASH Investor Event on December 8, 2025
Nov 03 2025
Newsfilter
Syndax Reveals Promising Data for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Accepted for ASH 2025 Presentation
Nov 03 2025
Newsfilter
Syndax Pharmaceuticals Q3 2025 Earnings Forecast
Nov 02 2025
SeekingAlpha
Show More News
